Mangoceuticals, Inc. (NASDAQ:MGRX – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 53,343 shares, a decrease of 41.7% from the October 15th total of 91,564 shares. Based on an average daily trading volume, of 369,429 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are sold short.
Analyst Ratings Changes
Several research analysts have weighed in on MGRX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a report on Monday, September 21st. Wall Street Zen upgraded Mangoceuticals to a “sell” rating in a report on Saturday, July 25th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Mangoceuticals has an average rating of “Sell”.
View Our Latest Research Report on MGRX
Mangoceuticals Stock Down 0.2%
Mangoceuticals (NASDAQ:MGRX – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.19) EPS for the quarter. Mangoceuticals had a negative net margin of 4,794.60% and a negative return on equity of 96.39%. The business had revenue of $0.07 million during the quarter.
About Mangoceuticals
Mangoceuticals, Inc. is a men’s health and wellness company that offers telehealth services through its online platform. The platform connects customers with healthcare providers for consultations and, when appropriate, prescription treatments. The company’s offerings have included treatments for erectile dysfunction, hair loss and testosterone-related concerns, as well as weight-management services. Prescriptions are fulfilled through pharmacy partners. Mangoceuticals primarily serves customers in the United States through its digital platform.
See Also
- Five stocks we like better than Mangoceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
